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Abstract: Biologics have advanced the therapy of adult and pediatric arthritis. They have been 
linked to rare serious adverse outcomes, but the actual risk of these events is controversial in 
adults, and largely unknown in pediatrics. Because of the paucity of safety and efﬁ  cacy data in 
children, pediatric rheumatologists often rely on the adult literature. Herein, we reviewed the 
adult and pediatric literature on ﬁ  ve classes of medicines: Tumor necrosis factor (TNF) inhibi-
tors, anakinra, rituximab, abatacept, and tocilizumab. For efﬁ  cacy, we reviewed randomized 
controlled studies in adults, but did include lesser qualities of evidence for pediatrics. For safety, 
we utilized prospective and retrospective studies, rarely including reports from other inﬂ  amma-
tory conditions. The review included studies on rheumatoid arthritis and spondyloarthritis, as 
well as juvenile idiopathic arthritis. Overall, we found that the TNF inhibitors have generally 
been found safe and effective in adult and pediatric use, although risks of infections and other 
adverse events are discussed. Anakinra, rituximab, abatacept, and tocilizumab have also shown 
positive results in adult trials, but there is minimal pediatric data published with the exception 
of small studies involving the subgroup of children with systemic onset juvenile idiopathic 
arthritis, in whom anakinra and tocilizumab may be effective therapies.
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Introduction
Juvenile idiopathic arthritis (JIA) affects between 1:1000–1:2000 children (Manners 
and Bower 2002). This condition is heterogeneous, divided into several subtypes based 
upon various clinical, laboratory, and epidemiological features (Petty et al 2004). 
Untreated, JIA can last well into adulthood, causing signiﬁ  cant long-term functional 
impairment (Minden et al 2000).
The last 10–15 years have witnessed an explosion in the development and 
application of medicines designed to target speciﬁ  c cytokines or cell surface 
receptors, therapies broadly referred to as biologics (Siddiqui 2007). In addi-
tion, etanercept, adalimumab, and abatacept all have indications for JIA; Table 1 
summarizes the biologics currently used or under consideration for JIA. Multiple 
biologics have been approved for use in rheumatoid arthritis (RA) as well as the 
spondyloarthropathies (SpA), including ankylosing spondylitis (AS) and psoriatic 
arthritis (PsA) (Siddiqui 2007). In addition, etanercept, adalimumab, and abatacept 
all have indications for JIA. Table 1 summarizes the biologics currently used or 
under consideration for use in JIA.
This article is intended as a comprehensive review on the potential role of bio-
logic therapy in pediatric arthritis. In contrast to previous review articles on this topic 
(Hashkes and Laxer 2006; Lovell 2006; Gartlehner et al 2008), however, we have 
elected to include data from adult studies as well. With respect to effectiveness data, Biologics: Targets & Therapy 2008:2(2) 230
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this decision is justiﬁ  ed in part by the likely genetic and 
mechanistic similarities between certain categories of JIA 
and their adult counterparts, such as RF-positive polyarticular 
JIA and RA; and enthesitis-related arthritis (ERA) and adult 
SpA (Ferucci et al 2005; Gensler and Davis 2006; Saxena 
et al 2006). In light of these similarities and the paucity of 
randomized trials in pediatrics, adult data is often the basis 
for our treatment decisions. Indeed, it was recently argued 
that the resources of pediatric rheumatology, both ﬁ  nancial 
and patient, are limited and might be put to better use than 
duplicating studies of therapies already proven successful in 
adults (Lehman 2007). We have therefore incorporated data 
from randomized double-blinded placebo-controlled studies 
from both adult and pediatric populations. Because of the 
limited numbers of pediatric randomized trials, we have also 
presented lesser quality data exclusively involving pediatric 
patients, such as cohort and retrospective studies.
Similarly, safety data from adult patients often has implica-
tions in the pediatric population, perhaps even more so than 
effectiveness data, since the safety of therapy probably does 
not depend upon the mechanism of the underlying disease. 
Consequently, pediatric rheumatologists should be aware of 
the lessons learned from our adult counterparts. We have there-
fore incorporated safety data from both the adult and pediatric 
literature from various sources, including randomized trials, 
registries, other large cohort studies, and case reports. Because 
of the heterogeneity of JIA, we have included adult safety and 
efﬁ  cacy data obtained from both RA and SpA patients.
Tumor necrosis factor inhibitors
Basic scientiﬁ  c rationale
A potential role for TNF in the pathogenesis of rheumatoid 
arthritis was initially reported in the 1980s (Hopkins and 
Meager 1988), and testing of a monoclonal antibody to TNF 
was begun in the mid-1990s. At present, there are three 
anti-TNF therapies available (Figure 1). Etanercept, a fusion 
protein consisting of the extracellular ligand-binding protein 
of the human 75-Kd TNF receptor linked to the Fc portion of 
human IgG1, is approved for RA, JIA (for patients 2–17 years 
old), PsA, AS, and plaque psoriasis (Zhou 2005). Inﬂ  iximab, a 
chimeric monoclonal antibody consisting of a murine immu-
noglobulin variable region directed against TNF fused with a 
human IgG1 Fc region, is approved for RA, Crohn’s disease, 
ulcerative colitis, AS, PsA, and plaque psoriasis (Feldmann 
et al 2004). Adalimumab, a fully humanized monoclonal anti-
body consisting of a variable region directed against TNF fused 
with a human Fc created from a phage display of human com-
ponents, is approved for use in RA, PsA, AS, JIA, and Crohn’s 
disease (Feldmann et al 2004). As shown in Figure 1, the fusion 
protein etanercept differs in its mechanism of action from the 
monoclonal antibodies inﬂ  iximab and adalimumab; the signiﬁ  -
cance of this difference in the treatment of arthritis and other 
rheumatological conditions is unclear (Rigby 2007).
Effectiveness
All told, at least 35 randomized, double-blind, placebo-
controlled trials have demonstrated the three TNF inhibitors 
Table 1 Biologics used in adult and pediatric arthritis.   Adapted from Gartlehner and colleagues (2008)
Generic name US trade name Mechanism of action Usual dosing FDA-approved uses Common JIA usage
Abatacept Orencia® T-cell costimulation
inhibitor
10 mg/kg (max 1000 mg) 
IV monthlya
RA, polyarticular JIA None
Adalimumab Humira® TNF inhibitor 24 mg/m2 (max 40 mg) 
SC every other week
RA, PsA, AS, Crohn’s, 
JIA
Polyarticular course 
JIA, uveitis
Anakinra Kineret® IL-1 receptor antagonist 1–2 mg/kg (max100 mg) 
SC daily
RA SOJIA
Etanercept Enbrel® TNF inhibitor 0.4 mg/m2 (max 25 mg) 
SC twice weeklyb
RA, polyarticular JIA 
(age 2–17), PsA, AS, 
plaque psoriasis
Polyarticular course 
JIA
Inﬂ  iximab Remicade® TNF inhibitor 3–10 mg/kg IV monthlya RA, Crohn’s, AS, PsA, 
plaque psoriasis, 
ulcerative colitis
Polyarticular course 
JIA, uveitis
Rituximab Rituxan® B-cell depletion 1000 mg IV x two doses 
two weeks apart
B-cell non-Hodgkin’s 
lymphoma, RA 
refractory to TNF 
inhibitors
RF-positive polyarticular 
JIA (rarely used)
Tocilizumab N/A IL-6 receptor antibody 2–8 mg/kg every two 
weeks
None SOJIAc
Abbreviations: AS, anklylosing spondylitis; IL, interleukin; IV, intravenous; JIA, juvenile idiopathic arthritis; N/A, not applicable; PsA, psoriatic arthritis; RA, rheumatoid arthritis; 
RF, rheumatoid factor; SC, subcutaneous; SOJIA, systemic onset juvenile idiopathic arthritis; TNF, tumor necrosis factor.
Notes: aThe ﬁ  rst doses are given on days 1, 15, and 29, followed by monthly; bCan be combined into a single weekly dose; cAvailable only on experimental basis in United States.Biologics: Targets & Therapy 2008:2(2) 231
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Figure 1 Mechanism of action of the TNF inhibitors. The binding of soluble TNF to its membrane-bound receptor induces cellular activation and inﬂ  ammation (A) Soluble TNF 
receptor fused to human Ig (etanercept) serves as a decoy receptor, binding to soluble TNF and preventing the TNF from binding to its membrane-bound receptor (B) The 
anti-TNF monoclonal antibodies bind to membrane-bound TNF, inducing apoptosis of cells involved in the inﬂ  ammatory pathway (C) Adapted from Rigby (2007).
Abbreviations: Ig, immunoglobulin; TNF, tumor necrosis factor.
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to be effective in the treatment of arthritis, including the 
spondyloarthropathies, all but one of which involved the 
adult population (Elliott et al 1994; Rankin et al 1995; 
Moreland et al 1997; Maini et al 1998; Moreland et al 
1999; Weinblatt et al 1999; Kavanaugh et al 2000; Lipsky 
et al 2000; Lovell et al 2000; Mease et al 2000; Van Den 
Bosch et al 2002; Brandt et al 2003; Davis et al 2003; Furst 
et al 2003; van de Putte et al 2003; Weinblatt et al 2003; 
Calin et al 2004; Keystone et al 2004a, 2004b; Klareskog et al 
2004; Lan et al 2004; St Clair et al 2004; Taylor et al 2004; 
van de Putte et al 2004; Antoni et al 2005a, 2005b; Marzo-
Ortega et al 2005; Mease et al 2005; Quinn et al 2005; van der 
Heijde et al 2005; Abe et al 2006; Breedveld et al 2006; van 
der Heijde et al 2006b; Westhovens et al 2006; Genovese 
et al 2007). To our knowledge, no negative studies have been 
published in the adult population, a record demonstrating 
the impressive effectiveness of this class of medicines in the 
management of inﬂ  ammatory arthritis. Recently, a negative 
trial was published in pediatrics; this will be discussed in 
detail below (Ruperto et al 2007).
Several nonrandomized studies have evaluated 
etanercept in refractory JIA, generally ﬁ  nding it to be 
safe and effective (Kietz et al 2002; Lahdenne et al 2003; 
Quartier et al 2003; Henrickson and Reiff 2004; Horneff et al Biologics: Targets & Therapy 2008:2(2) 232
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2004). In the largest of these studies, the German etanercept 
registry, 322 children with JIA were followed for a median 
of 12 months, with signiﬁ  cant improvements reported in 
each of the response criteria studied (swollen and tender 
joint counts, joints with limited range of motion, morning 
stiffness, physician and patient global assessment, CHAQ, 
and ESR), with remission reported in 26% (Horneff et al 
2004). Overall, treatment was well-tolerated, although 
there were 12 severe adverse events, including one case 
each of pneumonia requiring mechanical ventilation, 
thyroid cancer, and demyelination (Horneff et al 2004). 
Kietz and colleagues (2002) prospectively studied 22 
children with polyarticular course JIA for a median of 21 
months, ﬁ  nding substantial improvement in clinical and 
laboratory parameters in this cohort; treatment was well-
tolerated, with side effects limited to mild injection site 
reactions (Kietz et al 2002). Importantly, while Kietz and 
colleagues (2002) and Horneff and colleagues (2004) both 
reported prolonged duration of effectiveness, a different 
group reported rapid but nonsustained improvement; for 
example, ACR-30 scores were reported in 73% at 3 months, 
compared with only 39% at 12 months. In addition, 12 
of 61 patients in the latter study discontinued treatment 
because of severe adverse events, including pancytopenia, 
psychiatric disorders, uveitis, onset of inﬂ  ammatory bowel 
disease, optic neuritis, headaches, vasculitis, and weight 
gain (Quartier et al 2003).
The ﬁ  rst published randomized trial of a TNF inhibi-
tor in JIA involved etanercept. Lovell and colleagues 
(2000) enrolled 69 children 4–17 years of age with active 
polyarticular-course disease despite treatment with methotrex-
ate into the initial open-label phase of the trial. After three 
months, the 51 children in whom improvement was noted 
were enrolled into the four-month double blind phase, with the 
endpoint being disease ﬂ  are or 120 days, whichever occurred 
ﬁ  rst; of these 51 children, 25 were randomized to etanercept, 
and the remainder received placebo injections. Results at the 
end of the double-blind phase revealed disease ﬂ  ares occurred 
in 81% of placebo-treated children, compared with 28% of 
etanercept-treated children (p  0.05), with median times to 
ﬂ  are of 28 and116 days, respectively (p  0.05). There were 
no statistically signiﬁ  cant differences in adverse events during 
the blinded portion of the study, although two etanercept-
treated children were hospitalized: one for depression, and 
the other for gastroenteritis (Lovell et al 2000).
Children who completed the double-blind phase were eli-
gible to enroll into the second open-label phase; 58 children 
entered into the extension study, and 32 completed four years. 
Lovell and colleagues (2006b) reported improvements in all 
measures of disease activity and decreased corticosteroid 
usage among the children participating in the extension study, 
including those who did not complete the four-year study. 
Etanercept was generally well-tolerated; overall, there were 
225 patient-years of follow-up, with 8 serious infections, for 
a rate of 3 per 100 person-years. There were no lupus-like 
events, demyelinating lesions, or malignancies (Lovell et al 
2006b). Thus, etanercept appears to be safe and effective 
for longterm use in JIA. However, this study was faulted for 
bias introduced by the three-month run-in period, as well as 
for its failure to adjust for baseline differences between the 
groups, such as older age, longer disease duration, increased 
RF positivity, and increased corticosteroid usage among the 
control groups, differences that could bias towards showing 
an increased effect (Gartlehner et al 2008).
With respect to inﬂ  iximab, there are several uncontrolled 
retrospective and prospective studies, beginning with the 
case report by Elliot and colleagues (Elliott et al 1997; 
Lahdenne et al 2003; Schmeling and Horneff 2004; Gerloni 
et al 2005; De Marco et al 2007; Norambuena et al 2007). 
The three prospective studies generally showed effectiveness 
among those who tolerated it, although infusion reactions 
caused frequent discontinuations. For example, Gerloni and 
colleagues (2005) reported signiﬁ  cant improvements in the 
core measures of disease activity among 24 young adults 
with persistently active polyarticular JIA after 24 months 
of therapy, although six of the 24 dropped out (5 because 
of infusion reactions and one because of disease relapse), 
and 9 others did not complete two years of observation for 
unstated reasons. Lahdenne and colleagues (2003) enrolled 
14 polyarticular children, reporting ACR-75 improvements 
among six of nine treated with inﬂ  iximab for one year, 
although a total of six withdrew within the ﬁ  rst eight months: 
three because of infusion reactions, one with alopecia, one 
with macrophage activation syndrome, and one because of 
lack of efﬁ  cacy (Lahdenne et al 2003). Finally, de Marco 
and colleagues (2007) treated 78 JIA patients with inﬂ  iximab 
for up to three years, ﬁ  nding signiﬁ  cant and long-lasting 
improvements in the majority, but also reporting that 26 
discontinued because of adverse events, most commonly 
infusion reactions (De Marco et al 2007).
The results of a randomized controlled trial of inﬂ  iximab 
in JIA were published in 2007. In this study, children with 
active arthritis were randomized to receive either placebo 
for 14 weeks, followed by inﬂ  iximab 6 mg/kg at weeks 14, 
16, 20, and every 8 weeks thereafter for a total of 44 weeks; 
or inﬂ  iximab 3 mg/kg at weeks 0, 2, 6, and 14, followed by Biologics: Targets & Therapy 2008:2(2) 233
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placebo at week 16, then 3 mg/kg again at week 20 and every 
8 weeks thereafter. All patients received methotrexate co-
therapy throughout the study period. At week 14, the duration 
of the placebo-controlled portion of the study, more children 
in the 3 mg/kg group achieved an ACR-30 response com-
pared with the placebo group (37 of 58 [63.8%] vs 29 of 59 
[49.2%]), but this was not statistically signiﬁ  cant (p = 0.12), 
so the study failed to achieve its primary aim. Nevertheless, 
at week 14, children the inﬂ  iximab group had signiﬁ  cantly 
fewer joints with active arthritis. At the end of the 52-week 
study period, there were no signiﬁ  cant differences between 
the two treatment groups in the core set components (Ruperto 
et al 2007).
Safety analysis from the inﬂ  iximab study revealed that 
children in the low-dose inﬂ  iximab group were more likely 
to generate anti-inﬂ  iximab antibodies compared with those 
in the 6 mg/kg group, and were also more likely to have 
infusion reactions. Serious adverse events occurred in 19 of 
60 patients over 52 weeks treated with 3 mg/kg inﬂ  iximab, 
3 of 60 placebo patients over 14 weeks, and 3 of 57 patients 
over 38 weeks treated with 6 mg/kg inﬂ  iximab, so that after 
adjusting for length of treatment, they were most common 
in the low-dose inﬂ  iximab group and least common in the 
high-dose group. There were six serious infections, including 
one case of asymptomatic pulmonary tuberculosis, in the 
inﬂ  iximab-treated groups compared with two in the placebo 
patients; the authors did not adjust for length of treatment, 
but it appears that after doing so, no increased risk associated 
with drug therapy would be apparent. One placebo patient 
died of sepsis during the study; one inﬂ  iximab-treated patient 
with systemic onset JIA (SOJIA) died during the open-label 
phase of the study, six months after the ﬁ  nal dose, from 
cardiac complications of the underlying disease. No malig-
nancies were reported (Ruperto et al 2007).
Finally, there is emerging evidence that adalimumab 
may also be effective in JIA. Biester and colleagues (2007) 
reported on 16 patients with JIA who had previously failed 
treatment with conventional DMARDs and other TNF inhibi-
tors, ﬁ  nding a good response in 10, and a mild response in 
three (Biester et al 2007). In addition, data from a Phase III 
clinical trial of adalimumab in JIA presented at the 2006 
American College of Rheumatology conference, but not yet 
published, revealed signiﬁ  cantly higher clinical responses to 
the study drug compared with placebo, albeit with 4 unspeci-
ﬁ  ed serious adverse events compared with two in the placebo 
arm (Lovell et al 2006a).
For older children, pediatric dosing of the TNF inhibitors 
is similar to that used in adult medicine. The initial etanercept 
trials in adults used doses of 25 mg subcutaneously twice 
weekly (Brandt et al 2003; Davis et al 2003; Calin et al 2004), 
while the JIA trial used a dose of 0.4 mg/kg twice weekly, 
maximum of 25 mg per dose (Lovell et al 2000). However, 
because a single 50 mg dose has been shown to be equally 
effective in adults with rheumatoid arthritis or ankylosing 
spondylitis, the latter is often used in adult rheumatology 
(Keystone et al 2004b; van der Heijde et al 2006a). This 
dose has not been formally studied in pediatrics, but two 
small case series have shown that it may be equally effec-
tive (Kuemmerle-Deschner and Horneff 2007; Prince et al 
2007), and many practitioners have altered their practice 
accordingly. Dosing used in the unpublished adalimumab 
trial was 24 mg/m2 (Lovell et al 2006a), maximum of 40 mg 
every other week, the standard adult dose (Breedveld et al 
2006). Pediatric and adult dosing of inﬂ  iximab is typically 
3–10 mg/kg at weeks 0, 2, and 6 and q4–8 weeks thereafter 
(Lahdenne et al 2003; St Clair et al 2004; De Marco et al 
2007; Ruperto et al 2007).
The role of methotrexate co-therapy in pediatric patients 
using TNF inhibitors is uncertain. Randomized trials among 
adult patients with RA have shown that all three TNF inhibi-
tors are more effective as co-therapy with methotrexate than 
they are as mono-therapy (Maini et al 1998; Klareskog et al 
2004; Breedveld et al 2006). In the etanercept JIA trial, 
methotrexate was discontinued at the onset of the trial in all 
patients as per protocol, so no comparisons were available 
from this study, while in the inﬂ  iximab trial, all patients 
received methotrexate (Lovell et al 2000; Ruperto et al 2007). 
However, data from the German JIA etanercept registry 
revealed that patients treated with etanercept and methotrex-
ate in combination, compared with those treated with etaner-
cept alone, were more likely to achieve complete remission 
(29% vs 14%, p = 0.07) (Horneff et al 2004). Regarding 
safety, there are advantages to combining inﬂ  iximab with 
methotrexate or other disease-modifying anti-rheumatic 
drugs (DMARDs); combination therapy appears to protect 
against the development of anti-inﬂ  iximab antibodies, which 
have the unfortunate effects of inducing potentially danger-
ous infusion reactions and lessening the effectiveness of the 
therapy (Cheifetz and Mayer 2005; Bendtzen et al 2006). In 
practice, therefore, many pediatric practitioners use metho-
trexate as co-therapy with TNF agents in the treatment of RA 
and JIA, particularly when administering inﬂ  iximab.
The usefulness of methotrexate co-therapy in SpA 
remains unknown, as no trials have compared TNF inhibi-
tors alone with TNF inhibitors plus conventional DMARDs 
(Braun et al 2006). There is retrospective data, however. Biologics: Targets & Therapy 2008:2(2) 234
Stoll and Gotte
In a retrospective study of inﬂ  iximab-treated patients with 
inﬂ  ammatory arthritis, Kapetanovic and colleagues (2006) 
reported that absence of DMARD co-therapy was a risk factor 
for infusion reactions in RA, but not SpA, patients. However, 
there were only 76 SpA patients, and the negative ﬁ  ndings in 
this group may have been due to a lack of statistical power, 
since 7 of 10 patients with infusion reactions were using 
inﬂ  iximab mono-therapy, while such patients constituted 
only 41% of all inﬂ  iximab-treated SpA patients (Kapetanovic 
et al 2006). In addition, data in Crohn’s disease suggests that 
methotrexate can reduce the immunogenicity of inﬂ  iximab 
therapy (Baert et al 2003). Thus, when initiating inﬂ  iximab 
therapy in SpA patients, some practitioners will prescribe low-
dose methotrexate therapy with the primary aim of preventing 
infusion reactions, regardless of whether the added therapy 
will have an additive treatment effect. However, methotrexate 
co-therapy is not routinely used with etanercept.
Enthesitis-related arthritis (ERA) is a subtype of JIA that 
has clinical and genetic features similar to the adult spondy-
loarthropathies (Burgos-Vargas et al 2002a). Uncontrolled 
studies have demonstrated TNF inhibition to be effective for 
this particular sub-group (Henrickson and Reiff 2004; Tse et al 
2005). For example, Henrickson and Reiff (2004) demonstrated 
effectiveness in 8 children with ERA (age 8–16 years) treated 
with etanercept for one year in one patient and in two years 
in seven others. Tse and colleagues (2005) reported a good 
response in 10 children followed for one year (Tse et al 2005). 
Finally, Burgos-Vargas and colleagues (2007) presented data at 
the 2007 ACR conference of a randomized study of 26 children 
with ERA favoring inﬂ  iximab over placebo therapy. This 
parallels the success of TNF inhibition in adult SpA (Mease 
et al 2000; Van Den Bosch et al 2002; Brandt et al 2003; Davis 
et al 2003; Calin et al 2004; Antoni et al 2005a, 2005b; Marzo-
Ortega et al 2005; Mease et al 2005; van der Heijde et al 2005, 
2006a, 2006b; Genovese et al 2007). Importantly, adults with 
axial arthritis have generally demonstrated a poor response 
to conventional DMARDs, and an international consensus 
group recommended that TNF inhibitors be used as ﬁ  rst line 
therapy for patients with axial disease (Sampaio-Barros et al 
2000; Braun et al 2006; Chen and Liu 2006; Haibel et al 2007). 
Although two studies of children with juvenile SpA have dem-
onstrated modest beneﬁ  t of sulfasalazine therapy, neither of 
them differentiated those with axial symptoms from those with 
peripheral disease (Huang and Chen 1998; Burgos-Vargas et al 
2002b), and there is no data showing that traditional DMARDs 
are effective in the axial disease of ERA. Thus, our practice is 
to follow the adult spondyloarthritis guidelines and use TNF 
inhibitors as ﬁ  rst-line therapy, bypassing the conventional 
DMARDs. As noted above, however, when using inﬂ  iximab, 
we may use methotrexate as co-therapy to decrease the risk of 
infusion reactions.
Although TNF inhibitors have been generally effective 
in polyarticular JIA and ERA, they have been less so in 
SOJIA (Billiau et al 2002; Russo et al 2002; Katsicas and 
Russo 2005; Kimura et al 2005). The ﬁ  rst TNF inhibitor 
to be reported for treatment of this illness was etanercept. 
Kimura and colleagues (2005) reviewed 82 patients treated 
with etanercept, ﬁ  nding a good or excellent response in 46% 
and a poor response in 45% (Kimura et al 2005). Likewise, 
Russo and colleagues (2002) reported their experience with 
15 children with SOJIA; 14 of them did enjoy an initial 
response, but relapses were observed in nine, particularly 
when the doses of concomitant steroids and methotrexate 
were lowered (Russo et al 2002). Two observational studies 
comparing etanercept in children with different subtypes of 
JIA have found that the drug is less effective in children with 
systemic-onset disease compared with the other JIA subtypes, 
as did the randomized trial (Lovell et al 2000; Quartier et al 
2003; Horneff et al 2004). Inﬂ  iximab as well has generally 
been unsatisfying, particularly with respect to the systemic 
symptoms (Billiau et al 2002; Katsicas and Russo 2005). 
There is no data comparing the two, although our experience 
has been that inﬂ  iximab may be more effective. However, 
neither has been shown to be particularly effective, and as 
will be discussed below, therapies targeting interleukin-1 and 
interleukin-6 have generally shown more promise.
It has long been understood that a dangerous complication 
of pediatric arthritis is uveitis (Schaller et al 1969). Although 
initial case reports did show limited success with treatment 
with etanercept (Reiff et al 2001), subsequent studies have 
not borne this out (Schmeling and Horneff 2005; Smith et al 
2005; Saurenmann et al 2006). Indeed, a small controlled 
study enrolling 12 pediatric patients with uveitis found that the 
seven who received etanercept had no better response than the 
ﬁ  ve who received placebo (improvement was noted in three of 
seven etanercept-treated patients, versus two of ﬁ  ve placebo 
patients) (Smith et al 2005). In contrast, inﬂ  iximab has been 
reported to be effective for uveitis in several case reports 
(Richards et al 2005; Kahn et al 2006; Rajaraman et al 2006), 
with small comparative studies demonstrating it to be more 
effective than etanercept (Saurenmann et al 2006; Foeldvari 
et al 2007; Tynjala et al 2007). Foeldvari and colleagues 
(2007) surveyed the international pediatric rheumatology 
community, obtaining responses from 15 centers in which 
TNF inhibitors were used for this indication. The 15 centers 
entered 47 patients into this retrospective analysis, reporting Biologics: Targets & Therapy 2008:2(2) 235
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a good / moderate / poor response of 68%/32%/0% for 
inﬂ  iximab, versus 47%/15%/38% for etanercept, a statistically 
signiﬁ  cant difference (p  0.05). In this study, only three 
children used adalimumab, all of whom demonstrated a 
good response (Foeldvari et al 2007). Likewise, Tynjala 
and colleagues (2007) reported on their experiences in the 
management of pediatric JIA-associated uveitis at a single 
center, ﬁ  nding treatment failure in 54% of etanercept-treated 
patients versus 19% in the inﬂ  iximab group (Tynjala et al 
2007). Lastly, Saurenmann and colleagues (2006) performed 
a retrospective study of 21 children treated with TNF inhibi-
tors for uveitis, ﬁ  nding that inﬂ  iximab was signiﬁ  cantly more 
likely to induce a moderate or good response compared with 
etanercept (Saurenmann et al 2006). In the randomized trial 
of inﬂ  iximab in JIA, uveitis was an exclusion criteria, so its 
use was not evaluated in this population (Ruperto et al 2007). 
Two recent case series have found that adalimumab was effec-
tive in the management of pediatric uveitis (Vazquez-Cobian 
et al 2006; Biester et al 2007). Biester and colleagues (2007) 
reported that 16 of 18 children with uveitis responded well to 
adalimumab, while Vazquez-Cobian and colleagues (2006) 
reported decreased ocular inﬂ  ammation in 12/14 children, 
with improved vision and decreased use of topical steroids in 
the other two patients. Thus, treatment with one of the TNF 
inhibitor monoclonal antibodies has become the standard of 
care for children with uveitis who failed DMARD therapy.
Safety
Perhaps the most feared complication of TNF inhibitors is 
infection. There have been a considerable number of case 
reports and case series describing serious or opportunistic 
infections, including Pneumocystis jivoreci and Mycobacte-
rium tuberculosis (MTB), among adult and pediatric patients 
taking TNF inhibitors (Gomez-Reino et al 2003; Armbrust 
et al 2004; Kinder et al 2004; Tubach et al 2006; Kaur and 
Mahl 2007; Kesteman et al 2007), and national surveillance 
data from Spain conﬁ  rmed an increased risk of MTB relative 
to the background rate associated with RA (Gomez-Reino 
et al 2003; Kesteman et al 2007). Various groups interna-
tionally have established treatment guidelines regarding the 
risk of MTB, requiring all patients treated with TNF inhibi-
tors to receive a PPD in advance of therapy, and those with 
positive tests or historical or clinical signs of MTB treated 
for the infection prior to initiation of TNF inhibitor therapy 
(Furst et al 2002; Mariette and Salmon 2003; BTS 2005). 
Fortunately, these recommendations have been effective in 
reducing the risk of tuberculosis in RA patients treated with 
TNF inhibitors (Carmona et al 2005).
Although there is a general recognition that TNF 
inhibitors can predispose to infectious complications, the 
magnitude of the risk is unclear. They have been generally 
well tolerated during the randomized trials, with few showing 
statistically signiﬁ  cant increases in infections as compared 
with the placebo arm. Speciﬁ  cally, of the 36 trials referenced 
above, 34 reported safety data, and only two demonstrated a 
statistically signiﬁ  cant increase in serious infections (gener-
ally deﬁ  ned as those which were life-threatening or resulted 
in hospitalizations) in the treatment versus the control arms 
(Keystone et al 2004a; St Clair et al 2004) (Table 2). How-
ever, others revealed nonsigniﬁ  cant increases in infections 
in the drug arm (van de Putte et al 2004; Westhovens et al 
2006), and a meta-analysis published in 2006 limited to the 
two anti-TNF monoclonal antibodies and to RA trials did 
ﬁ  nd an overall increased risk of serious infections (Bongartz 
et al 2006). This study has been criticized on methodological 
grounds for several reasons, including its exclusion of etan-
ercept and its failure to take into account the longer duration 
of follow-up in the drug versus control arms in several of the 
studies (Dixon and Silman 2006). In addition, the deﬁ  nition 
of serious infections used in the varying trials was heteroge-
neous, and some of the patients may not have had infections 
that all clinicians would consider serious or life-threatening, 
such as bronchitis, community-acquired pneumonia, urinary 
tract infection, or cellulitis (Bongartz et al 2006). Thus, the 
data from the randomized controlled studies is suggestive, 
but not deﬁ  nitive, of an increased overall infection risk.
Important limitations of randomized double-blinded 
placebo-controlled trials, particularly insofar as interpreta-
tion of safety data is concerned, include the small number of 
patients studied, the relatively short duration of follow-up, 
and the exclusion of patient who may be at increased risk 
of complications (Pincus and Stein 1997) Indeed, the per-
centage of patients in daily practice who would qualify for 
a randomized trial may be as low as 21%–33%, reﬂ  ecting 
both lower disease activity and higher comorbidities in the 
excluded population (Zink et al 2006). Thus, large cohort data 
has been used to further evaluate the risk of TNF inhibitors 
in everyday practice. An important caveat of these studies 
is that TNF inhibitors are obviously preferentially used to 
treat patients with active disease, which is itself a risk fac-
tor for infection (Doran et al 2002), thus it is essential that 
cohort studies adjust for such potential confounding factors. 
In addition, knowledge of a patient’s treatment status may 
affect a physician’s management of a possible or diagnosed 
infection. Despite these limitations, large, comparative obser-
vational studies have made important contributions to our Biologics: Targets & Therapy 2008:2(2) 236
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Table 2 Summary of TNF inhibitor trials in inﬂ  ammatory arthritis
Source Disease Study drug Study
duration
(weeks)
n Placebo n Study drug
Serious
infections
Hematological
malignancies
Serious
infections
Hematological
malignancies
(Elliott et al 1994) RA INFL 4 24 0 0 49 1 0
(Rankin et al 1995) RA INFL 1–4a 12 0 0 24 0 0
(Moreland et al 1997) RA ETAN 12 44 0 0 136 0 0
(Maini et al 1998) RA INFL 26 14 0 0 87 2 0
(Moreland et al 1999) RA ETAN 24 80 1 0 134 0 0
(Weinblatt et al 1999) RA ETAN 24 30 0 0 59 1 0
(Kavanaugh et al 2000) RA INFL 12 7 1 0 21 2b 0
(Lipsky et al 2000) 
(ATTRACT)
RA INFL 54 88 7 0 340 21 1
(Lovell et al 2000) JIA ETAN 16 26 0 0 25 1 0
(Mease et al 2000) PsA ETAN 12 30 0 0 30 0 0
(Van Den Bosch et al 2002) SpA INFL 12 20 0 0 20 2 0
(Brandt et al 2003) AS ETAN 6a 17 0 0 16 0 0
(Davis et al 2003) AS ETAN 24 139 1 0 138 2 0
(Furst et al 2003) (STAR) RA ADAL 24 318 6 0 318 4 1d
(van de Putte et al 2003) RA ADAL 12 70 0 0 214 4 0
(Weinblatt et al 2003) 
(ARMADA)
RA ADAL 24 62 0 0 209 2 0
(Calin et al 2004) AS ETAN 12 39 0 0 45 0 0
(Keystone et al 2004a) RA ADAL 52 200 1 0 419 16c 1
(Keystone et al 2004b) RA ETAN 8a 53 0 0 367 5e 0
(Klareskog et al 2004) 
(TEMPO)
RA ETAN 24 228 10 0 456 20 0
(Lan et al 2004) RA ETAN 12 29 0 0 29 1 0
(St Clair et al 2004) RA INFL 54 282 6 0 722 40c 1
(Taylor et al 2004) RA INFL 54 12 No safety 
data
12 No safety data
(van de Putte et al 2004) RA ADAL 26 110 0 0 434 10 0
(Antoni et al 2005b) 
(IMPACT)
PsA INFL 16a 52 0 0 52 1 0
(Antoni et al 2005a) PsA INFL 24 100 NS 0 100 NS 0
(IMPACT II)
(Mease et al 2005) (ADEPT) PsA ADAL 24 162 1 0 151 1 0
(Marzo-Ortega et al 2005) AS INFL 30 14 0 0 28 0 0
(Quinn et al 2005) RA INFL 52 10 0 0 10 0 0
(van der Heijde et al 2005) 
(ASSERT)
AS INFL 24 78 0 0 201 2 0
(Abe et al 2006) RA INFL 14a 47 1 0 100 5 0
(Breedveld et al 2006) 
(PREMIER)
RA ADAL 104 257 7 1 542 12 1
(van der Heijde et al 2006) 
(TEMPO)
AS ADAL 24 107 1 0 208 0 0
(Westhovens et al 2006) RA INFL 22 363 6 0 721 24 0
(Genovese et al 2007) PsA ADAL 12 49 1 0 51 0 0
(Ruperto et al 2007) JIA INFL 52f 60 2 0 60 6 0
Abbreviations: ADAL, adalimumab; AS, ankylosing spondylitis; ETAN, etanercept; INFL, inﬂ  iximab; JIA, juvenile idiopathic arthritis; NS, not speciﬁ  ed; PsA, psoriatic arthritis; 
RA, rheumatoid arthritis; SpA, spondyloarthritis.
Notes: aDuration of blinded, placebo-controlled phase of study; bUnclear which of any of these were considered serious infections; cStatistically signiﬁ  cant (p  0.05); 
dOnset of symptoms before trial; eEtanercept arm was treated for 16 weeks versus 8 weeks for placebo patients; fThe placebo-controlled duration of the trial lasted only 14 
weeks, after which time all patients were treated with study drug for the duration of the 52-week study.Biologics: Targets & Therapy 2008:2(2) 237
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understanding of the risks of treatment with TNF inhibitors 
and other therapies. Several studies have identiﬁ  ed increased 
risks of serious infections, including those derived from 1459 
patients in the German RA registry (Listing et al 2005); 
23,733 patients in a Quebec cohort (Bernatsky et al 2007); 
5,326 US patients identiﬁ  ed through Medicare claims (Curtis 
et al 2007); and two separate single-center chart reviews 
comparing individual patients before and after initiation of 
TNF inhibitor use (Kroesen et al 2003; Salliot et al 2007). 
In contrast, three studies failed to show an increased infec-
tion risk: these were the British registry containing 8973 
RA patients (Dixon et al 2006); a cohort of 16,788 patients 
enrolled in the National Data Bank for Rheumatic Diseases 
(which was limited to hospitalizations for pneumonia) (Wolfe 
et al 2006); and a population of elderly Medicare patients 
in Pennsylvania (Schneeweiss et al 2007). It is difﬁ  cult to 
reconcile these disparate results, although failure to adjust 
for corticosteroid usage (Listing et al 2005; Bernatsky et al 
2007; Curtis et al 2007) may explain some of these ﬁ  nd-
ings, since high doses of corticosteroid usage appear to be 
an important risk factor for infections (Wolfe et al 2006; 
Bernatsky et al 2007; Salliot et al 2007; Schneeweiss et al 
2007). Alternatively, patients with increased risk of infections 
may not have been considered candidates for TNF inhibitors; 
infections in these high-risk patients could bias the results 
towards ﬁ  nding no difference between the DMARD and 
TNF inhibitor groups (Dixon et al 2006; Curtis et al 2007). 
Also, failure to incorporate infections that occurred after TNF 
therapy was discontinued may lead to an underestimation of 
infection risk, if therapy was discontinued because of symp-
toms suggestive of infections, but not diagnosed as such at 
the time of discontinuation; this was found to be the case in 
post-hoc analysis of the data from the British registry (Dixon 
et al 2007). In addition, this post-hoc analysis also revealed 
that limiting the analysis to the ﬁ  rst three months of therapy 
may reveal a sub-population of patients at increased risk of 
infection; since these patients often discontinue therapy, it 
follows that that the bulk of the patient-years of follow-up 
will be comprised of those who tolerated treatment well, thus 
potentially obscuring a signal (Dixon et al 2007). Indeed, 
analysis of the Swedish RA registry revealed that the relative 
risk of an infection leading to hospitalization associated with 
TNF inhibitor use decreases with each subsequent year of 
use (Askling et al 2007).
With respect to pediatrics, the etanercept trial did not 
reveal any signiﬁ  cant differences in the incidence of infec-
tions (Lovell et al 2000). Data from the four-year follow-
up, as noted above, revealed 8 serious infections over 225 
person-years; as described in the manuscript, these included 
gastroenteritis requiring hospitalization, aseptic meningitis 
secondary to varicella infection, sepsis, cellulitis requiring 
hospitalization for IV antibiotics, herpes zoster infection 
treated with IV acyclovir, appendicitis, a post-operative 
wound infection, and a dental abscess (Lovell et al 2006b). 
Likewise, the inﬂ  iximab trial did not appear to reveal an 
increased risk of serious infections, after adjusting for differ-
ent durations of treatment (Ruperto et al 2007). In addition, 
data from the German etanercept JIA registry consisting of 
322 patients with 592 patient-years of follow-up revealed 
only 20 infectious events, none of which were opportunis-
tic, although several were judged to be serious, including 
a case of sepsis (Horneff et al 2004). There are no cohort 
studies comparing pediatric DMARD to TNF inhibitor 
treated patients; thus, while serious infections have been 
observed in pediatric patients taking TNF inhibitors, these 
are uncommon, and contributions from the disease itself or 
other therapies cannot be excluded.
A second side effect potentially attributed to use of 
TNF inhibitors is malignancy, particularly hematological 
(Brown et al 2002; Geborek et al 2005). This perhaps is 
not unexpected, since the cytokine Tumor Necrosis Factor 
derived its name from studies from the 1970s in which a 
factor derived from the serum of bacille Calmette-Guerin 
(BCG)-immunized mice treated with lipopolysaccharide 
(LPS) was shown to induce lysis of transplanted tumors 
(Carswell et al 1975). Numerous studies have reported 
development of hematological malignancies among patients 
taking TNF inhibitors (Brown et al 2002), with one report 
of the lymphoma regressing after TNF inhibitor and coex-
istent DMARD therapy were withdrawn (Thonhofer et al 
2005). In practice, however, the actual risk of hematological 
malignancies may be limited. Of all the controlled studies 
referenced above, none of them actually demonstrated a 
statistically signiﬁ  cant increased risk of malignancies, hema-
tological or otherwise; only ﬁ  ve revealed any hematological 
malignancies in the TNF inhibitor-treated patients, and none 
showed more than one (Lipsky et al 2000; Furst et al 2003; 
Keystone et al 2004a; St Clair et al 2004; Breedveld et al 
2006) (Table 2). The Bongartz meta-analysis did ﬁ  nd an 
increased risk of malignancies among TNF inhibitor users 
in the RA inﬂ  iximab and adalimumab trials (Bongartz et al 
2006); however, in addition to the criticisms discussed 
above, it was also noted that the risk of malignancies in the 
control population was surprisingly low in those studies 
and may not have reﬂ  ected the general population (Dixon 
and Silman 2006).Biologics: Targets & Therapy 2008:2(2) 238
Stoll and Gotte
In addition, a number of cohort studies have evaluated the 
risks of malignancies among TNF inhibitor users compared 
with DMARD users or healthy controls, and the bulk of this 
data is reassuring. Three large cohort studies, including one 
in Sweden, one in the US and Canada, and one using data 
from 19,591 patients in the National Data Bank for Rheuma-
tologic Diseases (NDB), have failed to ﬁ  nd an increased risk 
of lymphoma or other malignancies among patients taking 
TNF inhibitors (Askling et al 2005a, 2005b; Setoguchi et al 
2006; Wolfe and Michaud 2007b). There was one contradic-
tory study from Sweden, which did ﬁ  nd an increased risk of 
lymphoma (Geborek et al 2005); importantly, this was criti-
cized in an accompanying editorial for several reasons, such 
as incomplete controlling for disease severity and low num-
bers of lymphoma cases identiﬁ  ed altogether, including an 
unusually low incidence in the control population (Franklin 
et al 2005). In addition, more recent analysis of the NDB did 
show a small but statistically signiﬁ  cant increased risk of 
skin cancer (Wolfe and Michaud 2007a). Thus, while active 
rheumatoid arthritis is a well-known risk factor for lymphoma 
(Baecklund et al 2006; Franklin et al 2006; Setoguchi et al 
2006), it appears that TNF inhibitors may not substantially 
increase the risk; indeed, it is plausible that to the extent 
that they are effective in lowering the inﬂ  ammatory burden, 
they may even decrease the associated risk of malignancies, 
although this has note been borne out in studies (Wolfe and 
Michaud 2004). There may, however, be an increased risk 
of skin cancers; this will need to be re-evaluated in future 
studies (Wolfe and Michaud 2007a). Finally, the name TNF 
itself may be a misnomer; there is more recent data suggest-
ing that the cytokine may actually promote cancer growth at 
physiological concentrations (Anderson et al 2004).
With respect to pediatrics, neither of the published TNF 
inhibitor trials revealed any malignancies, including data 
reported in the four-year open-label follow-up of the etan-
ercept study (Lovell et al 2000, 2006b; Ruperto et al 2007). 
Horneff and colleagues (2004) did report a case of thyroid 
cancer in a 19 year-old woman with JIA from their etanercept 
registry, but to our knowledge, there are no published reports 
of malignancies among children under 18 years of age that 
were attributed to TNF inhibitors.
Finally, a handful of additional rare side effects have been 
reported among TNF inhibitor users: these include episodes 
of demyelination consistent with multiple sclerosis (Sicotte 
and Voskuhl 2001; Tanno et al 2006); development of lupus 
autoantibodies and lupus-like syndromes (Ferraro-Peyret et al 
2004; De Bandt et al 2005; Fusconi et al 2007), occasionally 
associated with frank glomerulonephritis and other serious 
complications (Mor et al 2005; Chadha and Hernandez 
2006); pulmonary nodulosis reversible upon discontinuation 
of etanercept and concomitant leﬂ  unomide therapy (van Ede 
et al 2007); development of psoriasis, vasculitis, and other 
autoimmune diseases (Pirard et al 2006; Saint Marcoux 
and De Bandt 2006; Cohen et al 2007; Prescott et al 2007; 
Ramos-Casals et al 2007; Verschueren et al 2007); infusion 
reactions (Crandall and Mackner 2003); and depression 
(Lovell et al 2000). Even in the pediatric population, cases 
of optic neuritis, vasculitis, demyelination, drug-induced 
lupus, and psoriasis have been reported (Lepore et al 2003; 
Quartier et al 2003; Horneff et al 2004; Peek et al 2006), and 
as discussed above, discontinuations due to infusion reactions 
have been reported in 21%–22% of children enrolled in the 
three open-label inﬂ  iximab studies (Lahdenne et al 2003; 
Gerloni et al 2005; De Marco et al 2007).
Summary
TNF inhibitors have been used to treat arthritis for over 
10 years. In general, they have been found to be safe and 
effective in the adult and pediatric populations (Horneff 
et al 2004; Keystone 2005; Lovell et al 2006b). One notable 
exception is the recent inﬂ  iximab trial in JIA, although it was 
argued in an accompanying editorial that this likely reﬂ  ects 
study design and low patient numbers rather than an actual 
lack of efﬁ  cacy in the pediatric population (Lehman 2007). 
In addition, TNF inhibitors have generally been disappoint-
ing in the management of the systemic symptoms of SOJIA 
(Kimura et al 2005). Among patients with JIA, there is scant 
data comparing speciﬁ  c TNF inhibitors, with the exception of 
ﬁ  ndings of increased effectiveness of inﬂ  iximab versus etan-
ercept in the treatment of JIA-associated uveitis (Saurenmann 
et al 2006; Foeldvari et al 2007; Tynjala et al 2007). Perhaps 
the most signiﬁ  cant risk of therapy in both adults and children 
is serious infections, including tuberculosis. Fortunately, the 
adoption of treatment guidelines have mitigated the risk of 
this particular infection (Carmona et al 2005), but patients 
still do need to be cautioned about the risks of opportunistic 
and other serious infection.
Anakinra
Basic scientiﬁ  c rationale
Interleukin-1 (IL-1) is a highly inﬂ  ammatory cytokine which 
plays an important role in several inﬂ  ammatory conditions, 
including RA and SOJIA (Dinarello 1996; Cohen 2004; 
Pascual et al 2005). The action of IL-1 is regulated by the 
naturally occurring IL-1 receptor antagonist (IL-1Ra); this 
protein contains substantial sequence homology to IL-1, Biologics: Targets & Therapy 2008:2(2) 239
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but rather than causing activation through the IL-1 receptor, 
serves as a competitive inhibitor to IL-1 and is believed 
to play an endogenous anti-inﬂ  ammatory role (Thompson 
et al 1992). The IL-1Ra was cloned through recombinant 
technology from human monocytes in 1990 and modiﬁ  ed 
by the addition of a methionine residue at the amino termi-
nus to become the commercially available drug Anakinra 
(Eisenberg et al 1990; Cohen 2004) (Figure 2). It was initially 
studied in RA in 1996 and approved for use in RA by the 
FDA in 2001 (Campion et al 1996; Cohen 2004). Alternative 
methods for blocking IL-1 are under investigation, but this 
is beyond the scope of this review.
Effectiveness
There have been three placebo-controlled trials in RA 
studying safety and efﬁ  cacy of anakinra, and a fourth that 
evaluated safety only, the most frequently used dose being 
100 mg daily; in two of the studies, all patients were treated 
with methotrexate, a third required discontinuation of 
methotrexate therapy, and the safety trial allowed for indi-
vidual differences (Bresnihan et al 1998; Cohen et al 2002, 
2004; Fleischmann et al 2003). All three trials demonstrated 
moderate clinical beneﬁ  t, and improvements in radiographic 
progression were also documented (Bresnihan et al 1998; 
Jiang et al 2000; Cohen et al 2002, 2004; Fleischmann et al 
2003). However, although there are no randomized head-to-
head comparisons of TNF inhibitors with anakinra, a recent 
review of the existing studies reported that the TNF inhibitor 
trials generally reported better ACR responses compared with 
the anakinra trials (Gartlehner et al 2006).
The primary use of anakinra in the JIA population is in 
the treatment of patients with SOJIA, particularly during the 
systemic phase of the illness. The effectiveness of anakinra 
in therapy-resistant SOJIA was ﬁ  rst reported in 2004 in an 
abstract presented at the American College of Rheumatol-
ogy by Irigoyen and colleagues (2004), who surveyed the 
pediatric rheumatology community and summarized the 
experiences of seven patients from ﬁ  ve centers, reporting 
overall improvements in inﬂ  ammatory markers and arthri-
tis. Verbsky and White (2004) reported their experiences in 
two patients, both of whom experienced rapid and sustained 
resolution of symptoms at a dose of 2 mg/kg. Pascual and 
colleagues (2005) demonstrated prompt and dramatic 
improvement in both clinical and laboratory parameters in 
nine patients with refractory SOJIA. In this study, anakinra 
(2 mg/kg, maximum 100 mg) induced resolution of systemic 
symptoms within the ﬁ  rst week of treatment in seven of 
seven patients, as well as resolution of arthritic symptoms 
within days to weeks in six of eight patients; the remaining 
two patients had a partial response of their arthritis (Pascual 
et al 2005). Likewise, there have been several reports of the 
use of anakinra in patients with the adult counterpart, adult-
onset Still’s disease (Fitzgerald et al 2005; Vasques Godinho 
et al 2005; Kalliolias et al 2007; Kotter et al 2007). Virginia 
Pascual has provided scientiﬁ  c rationale of such therapy, 
showing upregulation of IL-1 related gene products in chil-
dren with active SOJIA, trending toward the gene expression 
levels seen in healthy controls following treatment with 
anakinra (Pascual et al 2005; Allantaz et al 2007).
Importantly, there have been negative ﬁ  ndings as well. 
Oglivie and colleagues (2007) reported that only one of six 
children with SOJIA had responded to anakinra. However, 
it was not clear whether the patients in their study had at the 
time of the trial mostly systemic or articular features, and our 
experience has been that anakinra is more effective at treating 
symptoms in the systemic phase of the disease, compared 
with the later, articular phase (Pascual et al 2005).
Additionally, Lequerre and colleagues (2008) reported 
that only ﬁ  ve of 20 children with SOJIA treated with 1-2 
mg/kg/day of anakinra achieved ACR-50 improvements at 
six months of therapy. In this study, the mean duration of dis-
ease was seven years and only 60% of children had systemic 
symptoms at the time anakinra therapy was initiated, while 
the remainder of the children had diffuse and severe arthritis 
without fever or rash. This contrasts to the more favorable 
experience of Pascual and colleagues (2005) in which all but 
two children had systemic features, again suggesting that 
anakinra may be more effective in the earlier systemic phase 
of the disease than in the later articular phase.
There is minimal data of anakinra use in other JIA sub-
types, none of which has been published to date. An open 
label study of 82 patients with polyarticular JIA presented 
only in abstract form, showed an ACR Pediatric 30 response 
in 58% of subjects (Ilowite et al 2003), a level which 
compares unfavorably with that reported in the open-label 
phase of the etanercept trial (~80%; Lovell et al 2000). In 
the double-blind phase of the anakinra trial, there were only 
small and nonstatistically signiﬁ  cant improvements in the 
anakinra-treated compared with the placebo-treated patients 
(Ilowite et al 2006).
Safety
In general, treatment with anakinra, both as monotherapy 
and in combination with methotrexate, has been shown to 
be well-tolerated in both adults and children (Bresnihan 
et al 1998; Cohen et al 2002, 2004; Fleischmann et al 2003; Biologics: Targets & Therapy 2008:2(2) 240
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Figure 2 Mechanism of action of anakinra. IL-1 binds to its receptor, inducing cellular activation and inﬂ  ammation (A) Exogenous IL-1 receptor antagonist (IL-1Ra; Anakinra) 
competes with IL-1 for binding to its receptor but does not induce cellular activation and inﬂ  ammation (B).
Abbreviation: IL, interleukin.
U U U U U Interleukin-1
receptor
A
Interleukin-1
Endogenous Interleukin-1
receptor antagonist
Activation
B
U U U U U
Exogenous
Interleukin-1
receptor antagonist
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Pascual et al 2005). Injection site reactions are the adverse 
effect most often reported and tend to be mild and improve 
over time (Bresnihan et al 1998; Pascual et al 2005). Patients 
should be cautioned that the injections themselves can be 
quite painful, however. In the study published by Pascual 
and colleagues (2005), one patient with underlying myo-
cardial dysfunction developed two episodes of vomiting 
and hypotension with anakinra administration. Of the four 
randomized trials in RA, one did not report any serious 
infections (Cohen et al 2002), and two others found the 
risks between the placebo and anakinra arms to be similar 
(Bresnihan et al 1998; Cohen et al 2004). The largest of the 
four trials, enrolling 1399 patients, did ﬁ  nd an increased risk 
of serious infections in the anakinra-treated patients (2.1% 
vs 0.4%), albeit not statistically signiﬁ  cant. Most of the 
infections consisted of pneumonia or cellulitis; there were 
no opportunistic infections or cases of TB and none were 
fatal (Fleischmann et al 2003). A three-year update on this 
study revealed no signiﬁ  cant changes in the rate of adverse 
events over this time frame (Fleischmann et al 2006). Tran-
sient cytopenias have also been reported in study patients, 
as well as anecdotally (Bresnihan et al 1998; Cohen et al 
2002; Quartuccio and De Vita 2007). Finally, anecdotal 
case reports of cardiac death in a 29 year-old woman with Biologics: Targets & Therapy 2008:2(2) 241
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adult-onset Still’s disease, visceral leishmaniasis in a 9-year-
old girl living in an endemic area in southeastern France, 
tuberculosis reactivation, and multiple-organism sepsis in 
a 66-year-old RA patient have been documented in patients 
taking anakinra (Turesson and Riesbeck 2004; Kone-Paut 
et al 2007; Ruiz et al 2007; Settas et al 2007).
Summary
Interleukin-1 blockade by anakinra interferes with the 
pro-inﬂ  ammatory cascade important in the pathogenesis of 
chronic arthritis. Although its role in the therapy of RA and 
polyarticular JIA is undeﬁ  ned, anakinra is generally well-
tolerated and does appear to be very effective in treating the 
systemic features of SOJIA (Pascual et al 2005). However, 
because the pediatric studies were based upon small groups 
of children, overall pediatric safety data is limited.
Rituximab
Basic scientiﬁ  c rationale
Rituximab is a chimeric monoclonal antibody directed against 
the CD20 surface antigen present on B-cells; it consists of a 
human IgG1 heavy chain fused to a murine anti-CD20 vari-
able receptor (Grillo-Lopez et al 1999). The CD20 receptor 
is present on pre-B, naïve, memory, and mature B-cells, but 
not on plasma cells or stem cells, nor on any other cell lin-
eages, hence the speciﬁ  city of rituximab for B-cells (Leandro 
et al 2002). Approved by the FDA for use in CD20+ B-cell 
lymphomas in 1997, it has since been applied to a variety of 
autoimmune diseases, perhaps most prominently RA. The 
FDA approved it for use in RA refractory to TNF inhibitors 
in 2005 (Smolen et al 2007).
Effectiveness
Compared with the TNF inhibitors, the amount of safety and 
effectiveness data for rituximab in RA is limited. There have 
been two randomized, double-blinded, placebo-controlled 
trials in RA, both of which showed statistically signiﬁ  cant 
beneﬁ  cial effects, as did a randomized, placebo-controlled, 
open-label trial; dosages used in these studies were 500 mg 
or 1000 mg IV x two doses, two weeks apart (Edwards et al 
2004; Cohen et al 2006; Emery et al 2006). Additional impor-
tant information that has emerged from these trials includes 
effectiveness of rituximab in patients who have failed TNF 
inhibitors, increased tolerance of the infusion when patients 
are pre-medicated with methylprednisolone, and lack of an 
additive effect with daily oral corticosteroids or with cyclo-
phosphamide infusions (Edwards et al 2004; Cohen et al 
2006; Emery et al 2006). In addition, in all three trials, nearly 
complete B-cell depletion was noted in the rituximab-treated 
patients, with recovery in two of the studies noted beginning 
at 16 weeks (Edwards et al 2004; Cohen et al 2006; Emery 
et al 2006). Additional information about the kinetics of B-cell 
recovery was obtained by Leandro and colleagues (2006), who 
observed that B-cell repopulation in a cohort of 24 RA patients 
took a mean of 8 months and began with a naïve population 
that eventually matured. Relapses were noted to correlate with 
increased numbers of mature B-cells in the peripheral blood.
Of substantial relevance to the pediatric patient popu-
lation, in which the RF-positive population comprises 
approximately 10% of children with polyarticular arthritis 
(Krumrey-Langkammerer and Hafner 2001), two of the 
trials compared the effectiveness of rituximab therapy in the 
RF-positive and RF-negative patient populations. One found 
that the drug was equally effective in both populations, while 
the other found that there were no differences between RF-
negative placebo patients compared with RF-negative study 
drug patients, although the placebo patients in this study had 
an unusually high response rate, complicating interpretation 
of the data (Cohen et al 2006; Emery et al 2006).
To our knowledge, there are only three case reports of 
rituxumab use in JIA patients, one of whom was an adult at 
the time of the study. Kuek and colleagues (2006) adminis-
tered rituximab to a 26-year-old woman with RF-negative 
polyarticular JIA of 18 years duration, reporting improve-
ments in her functional status and tapering of concomitant 
corticosteroid therapy (Kuek et al 2006). El-Hallak and 
colleagues (2007) reported on experiences in 10 children 
from a single center with various autoimmune conditions 
treated with rituximab with the lymphoma protocol of 
375 mg/m2 weekly x four weeks, one of whom had polyar-
ticular JIA; her rheumatoid factor status was not reported. 
This patient did respond well to the therapy (El-Hallak et al 
2007). Finally, Dass and colleagues (2007) reported on 
three patients who developed psoriasis following rituximab 
use, one of whom was a 17-year-old girl with long-standing 
B27+, RF-poly-arthritis, who had an unsatisfactory response 
for six months, before developing psoriasis, pan-uveitis, and 
Achilles tendon rupture (Dass et al 2007).
Safety
Most of the safety data for rituximab comes from its use 
in lymphoma, since over 700,000 patients have received 
this therapy (Solal-Celigny 2006). The most common side 
effects are infusion reactions, which are typically mild and 
tend to resolve after the ﬁ  rst dose, although they rarely can 
be quite severe, resulting in hypotension, bronchospasm, and Biologics: Targets & Therapy 2008:2(2) 242
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occasionally even death (Kimby 2005; Mohrbacher 2005). 
Cases of serum sickness, transient cytopenias, and tumor 
lysis syndrome have also been reported, although the latter 
is unique to its use in lymphoma (Todd and Helfgott 2007). 
With respect to infections, the overall oncology experience 
has been that treated patients have not had more severe or 
opportunistic infections than would otherwise be expected, 
given the population, although reactivation of Hepatitis B has 
been reported (Tsutsumi et al 2005; Solal-Celigny 2006).
None of the three randomized, controlled trials in RA 
demonstrated a statistically signiﬁ  cant increased infection 
risks, although one did demonstrate a nonsigniﬁ  cant increased 
risk; none of the studies reported cases of tuberculosis or 
opportunistic infections (Edwards et al 2004; Cohen et al 
2006; Emery et al 2006). Likewise, data from observational 
studies in adults with RA has generally been reassuring, with 
mild infusion reactions being the most commonly reported 
adverse event (Leandro et al 2002; Kneitz et al 2004; Moore 
et al 2004; Gottenberg et al 2005; Higashida et al 2005; 
Brulhart et al 2006; Finckh et al 2007; Jois et al 2007; Popa 
et al 2007). When serious infections have occurred, it was 
generally unclear whether they were related to the study drug, 
with the exception that one patient in the study by Popa and 
colleagues (2007) did develop hypogammaglobulinemia 
and respiratory infections associated with bronchiectasis. 
Recently, Dass and colleagues (2007) published a case report 
of three patients who developed psoriasis during rituximab 
use. They were a 17-year-old B27-positive, RF-negative JIA 
patient, a 52-year-old woman with RF-positive RA, and a 
26-year-old lupus patient (Dass et al 2007).
As noted above, there is limited published use of this 
therapy in children with arthritis. There is, however, pediatric 
data from oncological uses, as well as in other autoimmune 
diseases, including idiopathic thrombocytopenic purpura 
and pediatric lupus. Most of these studies have demonstrated 
safety and effectiveness, with major side effects being infu-
sion reactions and in some cases, serum sickness (Quartier 
et al 2001; Marks et al 2005; Wang et al 2005; Bennett et al 
2006; Parodi et al 2006; El-Hallak et al 2007; Rao et al 2007). 
Interestingly, serum sickness has not been reported much in 
RA patients, although Todd and Helfgott (2007) speculated 
that this may be due to under-reporting caused by confusion 
with arthritis symptoms. One exception to the generally 
benign experience with rituximab in pediatric patients was 
the retrospective study by Willems and colleagues (2006), 
who reported that of 11 pediatric SLE patients treated with 
rituximab, 5 had severe adverse events, including two with 
septicemia and four with signiﬁ  cant cytopenias.
Finally, the FDA recently issued an advisory warning 
about two patients with lupus who developed fatal infection 
with JC virus, the etiologic agent of progressive multifocal 
leukoencephalopathy (PML) (2007); there have also been 
several case reports of PML occurring in oncology patients 
treated with rituximab, all of whom were also treated with 
other cytotoxic chemotherapeutic agents (Goldberg et al 
2002; Matteucci et al 2002; Steurer et al 2003; Freim Wahl 
et al 2007). Details of the co-therapies used by the two lupus 
patients were not released by the FDA.
Summary
Rituximab is developing a strong effectiveness record in RA, 
and has been safely used in a variety of other pediatric and 
adult rheumatological conditions (Quartier et al 2001; Marks 
et al 2005; Pijpe et al 2005; Wang et al 2005; Bennett et al 
2006; Parodi et al 2006; Scheinberg et al 2006; El-Hallak 
et al 2007; Rao et al 2007; Tanaka et al 2007). A consensus 
statement released in 2007 recommended use in RF-positive 
patients who failed TNF inhibitor therapy and who do not have 
a history of chronic infections. This statement also advised 
pre-medication with methyl-prednisolone and concomitant 
use of methotrexate (Smolen et al 2007). However, pediatric 
data is limited to case reports. Although RA trial data can 
arguably be extrapolated to RF-positive polyarticular JIA 
patients, the role of rituximab in RF-negative RA has not 
been well-deﬁ  ned, and there is minimal data in the spondy-
loarthropathies. In addition, although rituximab is generally 
well tolerated, it bears repeating that there have been rare 
reports of life-threatening infusion reactions and fatal viral 
infections such as PML (Goldberg et al 2002; Steurer et al 
2003; Kimby 2005; 2007; Freim Wahl et al 2007).
Abatacept
Basic scientiﬁ  c rationale
The concept behind abatacept was triggered by basic sci-
ence knowledge of mechanisms involved in T-cell activa-
tion. As reviewed by Salomon and Bluestone (2001), T-cell 
activation generally requires two speciﬁ  c events: the ﬁ  rst 
is presentation of the peptide-MHC complex to the T-cell 
receptor; the second is co-stimulation through any number of 
surface receptors present on antigen-presenting cells (APCs) 
and T-cells, perhaps most importantly the CD80/CD86 on 
APCs and CD28 on T-cells (Salomon and Bluestone 2001). 
Cytotoxic T-cell Lymphocyte Antigen-4 (CTLA4) bears 
structural similarity to CD28, but has much higher afﬁ  n-
ity for CD80 and CD86 (Bluestone et al 2006). Linsley 
and colleagues (1991) designed a molecule consisting of Biologics: Targets & Therapy 2008:2(2) 243
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CTLA4 fused to a modiﬁ  ed human Fc region, showing that 
it inhibited in vitro immune responses; this fusion protein, 
initially known as CTLA4-Ig, has since been named abata-
cept (Figure 3). Abatacept was initially studied in transplant 
rejection, and its initial clinical application was in psoriasis, 
but it has largely been used in RA, for which purpose it was 
approved by the FDA in 2005 (Abrams et al 1999; Bluestone 
et al 2006). Recently, abatacept was also approved for use 
in polyarticular JIA.
Effectiveness
Abatacept has been studied in ﬁ  ve randomized, placebo-
controlled trials in RA (Moreland et al 2002; Kremer et al 
2003, 2005, 2006; Genovese et al 2005). In three of the 
studies, participants were required to use methotrexate as 
co-therapy (Kremer et al 2003, 2005, 2006); in one trial, 
patients were required to take any oral DMARD or anakinra 
as concomitant therapy (Genovese et al 2005), and in one, 
DMARD therapy was not permitted (Moreland et al 2002). 
Abatacept was effective in all of the trials, more so at 
10 mg/kg than 2 mg/kg; dosing was at day 1 and 15, then 
monthly (Moreland et al 2002; Kremer et al 2003, 2005, 
2006; Genovese et al 2005).
Results of an open-label trial in JIA were presented at the 
2006 ACR conference, but have not yet been published. In 
this study, 190 children with JIA were treated with abatacept 
10 mg/kg IV on days 1, 15, and monthly for four months. 123 
of the 190 children (65%) demonstrated ACR-30 responses, 
and the mean percent reduction in the number of active joints 
from baseline was 56%. 20 withdrew from the study, 17 for 
lack of efﬁ  cacy, one for adverse events, one for withdrawal 
of consent, and one for undisclosed reasons (Lovell et al 
2006c). Safety data presented in the following year revealed 
one case of leukemia diagnosed at day 89 of the open-label 
phase, which the study investigators suspect may have been 
present prior to enrollment, and a case of varicella encepha-
litis in a placebo-treated patient in the double-blind phase of 
the study (Lovell et al 2007).
Safety
Abatacept has generally been well-tolerated. In three of 
the trials, severe adverse effects were more common in the 
placebo arms than in the 10 mg/kg abatacept arm, generally 
related to increased disease ﬂ  ares (Moreland et al 2002; 
Kremer et al 2003, 2005); only one study reported increased 
severe infections in the abatacept arm, a nonsigniﬁ  cant dif-
ference of 3.9% vs. 2.3% (Kremer et al 2006). There were 
no reported cases of tuberculosis or opportunistic infections 
among patients taking abatacept. In addition, as noted above, 
preliminary data indicates that abatacept was well-tolerated in 
JIA patients, although these results have yet to be published 
(Lovell et al 2007). Abatacept was also well tolerated in 
an open-label psoriasis study, with no serious infections or 
other serious adverse events, aside from hospitalization for 
an asthma ﬂ  are in a patient with pre-existing asthma (Abrams 
et al 1999). To our knowledge, there are no published reports 
of adverse reactions to abatacept, beyond those detailed in 
the published trials.
Summary
Abatacept represents a successful transition from basic sci-
ence research to clinical applications. It appears to be safe and 
effective in RA, showing success even in patients refractory 
to TNF inhibitors (Genovese et al 2005). Preliminary data 
likewise reveals effectiveness in JIA (Lovell et al 2006c). 
One theoretical concern with abatacept is that CTLA4 trans-
mits negative signals to T-cells, so it could potentially have a 
pro-inﬂ  ammatory effect, particularly late in the immune reac-
tions, when negative signaling through CTLA4 dominates 
(Bluestone et al 2006). Although this theoretical concern has 
not been borne out by the clinical data, overall experience, 
particularly in pediatrics, is limited.
Tocilizumab
Basic scientiﬁ  c rationale
There is data implicating interleukin-6 (IL-6) in the pathogen-
esis of RA, with particular genetic polymorphisms conferring 
an increased risk of the disease and elevated serum levels 
correlating with disease activity (de Benedetti et al 1991; 
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Figure 3 Mechanism of action of abatacept. Under normal circumstances, CD80/86 
on antigen-presenting cells (APC) binds to CD28 on T-cells, providing a second signal 
resulting in T-cell activation following peptide / MHC recognition by the T-cell receptor 
(A). CTLA4, another receptor on the surface of T-cells, binds to CD80/86 with increased 
afﬁ  nity, transmitting negative signals to the T-cell (B). Soluble CTLA4-Ig (abatacept) binds 
to CD80/86, preventing it from binding to CD28 (C). Copright © 2007 Blackwell Publish-
ing. Reproduced with permission from Todd DJ, Costenbader KH, Weinblatt MT. 2007. 
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Rooney et al 1995; Fishman et al 1998; Ogilvie et al 2003). 
Sato and colleagues (1993) constructed a partially humanized 
monoclonal antibody against the IL-6 receptor, by fusing 
human IgG1 with a murine CDR directed against the receptor 
for the human cytokine. This antibody, initially called MRA, 
is now known as tocilizumab. It has not been approved by 
the FDA and is generally available in the United States for 
research purposes only.
Effectiveness
There have been ﬁ  ve randomized, placebo-controlled trials 
of tocilizumab in RA, with all ﬁ  ve showing effectiveness 
at doses from 4–8 mg/kg, and lesser effects at lower doses 
(Choy et al 2002; Nishimoto et al 2004, 2007; Maini et al 
2006; Smolen et al 2008). In one trial, methotrexate did not 
demonstrate an additive effect at the therapeutic doses of 
tocilizumab (Maini et al 2006).
In pediatrics, tocilizumab has largely been studied in 
SOJIA patients; two open-label studies have been published 
(Woo et al 2005; Yokota et al 2005). In the study by Woo and 
colleagues (2005), 18 children with methotrexate-refractory 
disease for at least 3 months received tocilizumab at doses 
of 2 mg/kg, 4 mg/kg, or 8mg/kg; follow-up periods were, 
respectively, 4, 6, or 8 weeks. The efﬁ  cacy analysis was only 
based upon 15 children, as there were unspeciﬁ  ed protocol 
violations in three. Overall, treatment led to improvements in 
clinical and laboratory features, albeit less so at the 2 mg/kg 
dose. However, three children required corticosteroid rescue 
therapy during this short trial, one each at each of the three 
dosages (Woo et al 2005).
Yokota and colleagues (2005) enrolled 11 children age 
2–19 into a dose-escalating trial, in which children received 
three doses of tocilizumab 2 mg/kg every two weeks, with 
the dose increased stepwise to 4 mg/kg and again to 8 mg/
kg if the lower doses failed to maintain CRP levels below 
1.5 mg/dL. Treatment was effective, leading to improve-
ments in multiple parameters, including synovitis, markers 
of inﬂ  ammation, fever ﬂ  uctuations, hemoglobin, and platelet 
count. Three of the 11 children had the disease stabilized 
based upon CRP measurements at the 2 mg/kg dose, ﬁ  ve 
required the 4 mg/kg dose, and the remainder three were sta-
bilized at the highest dose; all three children who received the 
8 mg/kg dose had ACR-70 responses. No children required 
rescue therapy (Yokota et al 2005).
Results from a phase III clinical trial in SOJIA were 
recently published. In this study, 56 children with SOJIA 
were treated with tocilizumab open-label at 8 mg/kg every 
other week for six weeks. 43 met responder criteria and were 
enrolled into the 12-week long double-blind withdrawal 
phase; 83% of placebo patients compared with 20% of 
tocilizumab-treated patients withdrew from the study (Yokota 
et al 2008). An additional study presented at the 2006 ACR 
conference evaluated the safety and efﬁ  cacy of tocilizumab 
in a 12-week long open-label trial of 19 children with poly-
articular JIA, showing improvement in clinical parameters; 
however, of the 19 children, three were hospitalized: two for 
gastroenteritis and one for sensory disturbance (Imagawa 
et al 2006).
Safety
In the open-label pediatric trial published by Woo and col-
leagues (2005), multiple adverse events were reported: there 
were 9 infections in total, although the only ones that were 
considered serious were chicken pox and herpes simplex 
oral ulcerations. Other serious adverse events were disease 
ﬂ  ares in two patients and transient pancytopenia in one. 
In addition, lymphopenia was noted in 15 of 18 patients 
and transient increases in liver function tests were noted in 
three (Woo et al 2005). In contrast, in the study by Yokota 
and colleagues (2005), therapy was well-tolerated, without 
any serious adverse events; the only potentially infectious 
adverse events over the 80 days of follow-up were URIs in 
two children and pustules on the extremities of three. No 
cytopenias or any other major laboratory abnormalities were 
reported (Yokota et al 2005). In the phase III study in SOJIA, 
safety analysis revealed two serious adverse events during 
the open-label lead in phase, consisting of one anaphylactic 
reaction and one case of gastrointestinal hemorrhage; two 
serious adverse events during the double-blind phase, consist-
ing of an EBV infection associated with marked increases 
in transaminases in a tocilizumab-treated patient and a 
case of Zoster in a placebo patient; and 13 serious adverse 
events in an open-label extension phase lasting 48 weeks 
and enrolling 50 children. Most of these did not appear to 
be life-threatening, with the exception of an anyphylactic 
reaction that led to drug discontinuation (Yokota et al 2008). 
Finally, in the trial of tocilizumab in polyarticular-JIA, three 
of 19 children were hospitalized over 12 weeks (Imagawa 
et al 2006). There is a case report of the sudden onset of 
fatal congestive heart failure and interstitial pneumonitis in 
a patient with severe chronic infantile neurologic, cutaneous, 
and articular (CINCA) syndrome who had responded well to 
tocilizumab for two months prior to his rapid demise; despite 
the sudden onset of the symptoms, the authors excluded the 
possibility of an infection causing the patient’s deterioration 
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Likewise, therapy has generally been tolerated in the 
adult RA patients, although three of the ﬁ  ve studies showed 
nonstatistically signiﬁ  cant increases in serious infections in 
the drug arm (Nishimoto et al 2004, 2007; Maini et al 2006), 
while another did not present detailed analysis of the serious 
infections (Choy et al 2002). There was one reported death, 
secondary to Epstein-Barr virus reactivation, in the tocili-
zumab arm of one of the studies (Nishimoto et al 2004).
Summary
Tocilizumab may have an important role in both RA and 
SOJIA (Choy et al 2002; Nishimoto et al 2004, 2007; Woo et al 
2005; Yokota et al 2005, 2008; Maini et al 2006; Smolen et al 
2008); its role in other subtypes of JIA is undetermined. With 
respect to safety, several randomized controlled trials in RA 
have shown increases in serious infections in the tocilizumab 
groups, with one reported death (Nishimoto et al 2004, 2007; 
Maini et al 2006); importantly, all of these trials were dose-
ranging and therefore had more patients in the tocilizumab 
arms, but this is clearly an issue that bears further monitoring. 
In the SOJIA trials, small numbers of enrolled patients preclude 
deﬁ  nitive conclusions, although occurrences of lymphopenia 
in one of the trials, as well as three hospitalizations over 12 
weeks in another, do suggest a need for caution (Woo et al 
2005; Imagawa et al 2006), as does the sudden onset of inter-
stitial pneumonia and congestive heart failure in a CINCA 
patient whose disease had been brought under good control 
with therapy (Matsubara et al 2006). Finally, as noted above, 
tocilicumab has not been approved by the FDA, so would only 
be available in the United States on an experimental basis.
Combination biological therapy
Theoretically, there may exist a sound rationale for combin-
ing therapy with inhibitors of TNF and other biologics, such 
as anakinra. The complexity of the cytokine and intracellular 
signaling pathways makes it unlikely that a single biologic, 
targeting a single cytokine or cell surface receptor, will be 
uniformly or completely effective, and indeed, success is 
measured in improved responses, not complete remission 
(Isaacs et al 1999; van den Berg 2002). In several different 
animal models of arthritis, combination therapy with inﬂ  ix-
imab and anakinra has been signiﬁ  cantly more effective than 
mono-therapy with either agent (Bendele et al 2000; Feige 
et al 2000; Zwerina et al 2004). Therefore, the possibilities 
of combination therapy have attracted clinical interest; unfor-
tunately, data to date has not been rewarding.
To our knowledge, Genovese and colleagues (2004) was 
the ﬁ  rst to formally evaluate combination therapy in humans. 
In this study, 242 adult RA patients previously untreated with 
TNF inhibitors or anakinra were randomized to receive etan-
ercept + anakinra placebo, etanercept + anakinra, and half-
dose etanercept (25 mg weekly) + anakinra. After 24 weeks, 
the three groups had generally equivalent responses, with the 
full-dose etanercept arm actually showing a higher ACR20 
response than the etanercept–anakinra combination arm. 
However, safety analysis revealed signiﬁ  cant differences, 
with both combination arms being associated with signiﬁ  -
cantly increased incidences of serious adverse events and 
events leading to withdrawal. For example, serious infections 
were reported in 0/80 etanercept controls, compared with 
3/81 half-dosage etanercept – anakinra combination patients 
and 6/81 full-dosage etanercept – anakinra combination 
patients; there was one death in the full-dosage combina-
tion arm: respiratory insufﬁ  ciency triggered by pneumonia 
in a patient with pre-existing pulmonary ﬁ  brosis (Genovese 
et al 2004).
Two recent studies have evaluated combination therapy 
involving abatacept. Weinblatt and colleagues (2006) 
randomized 1441 RA patients to abatacept or placebo. 
An important and unique aspect of this trial is that some 
of the patients in each group were on background biologic 
therapy while others were not, thus permitting analysis of 
the safety of abatacept with or without background biologic 
therapy. Overall, the abatacept and placebo arms were simi-
lar with respect to overall adverse events, serious adverse 
events, and discontinuations, with a small but statistically 
nonsigniﬁ  cant increase in serious infections in the patients 
receiving abatacept (2.6% vs. 1.7%). However, in the sub-
group of patients on background biologic therapy, serious 
infections were reported in 6/103 (5.8%) of abatacept-treated 
patients, vs. 1/64 (1.6%) control patients. Post-hoc efﬁ  cacy 
analysis was performed in this safety trial; no evidence of an 
additive effect was demonstrated (Weinblatt et al 2006).
Finally, Weinblatt and colleagues (2007) randomized 
121 patients with an incomplete response to etanercept to 
receive abatacept or placebo on top of pre-existing etaner-
cept therapy. The abatacept dose in this study was 2 mg/kg 
on days 1, 15, and 30 followed by every four weeks for a 
total of six months, at which point the dose was increased 
to 10 mg/kg for another six months. Overall, there were 
minimal differences in effectiveness between the groups, 
although the abatacept 2 mg/kg arm did have an increased 
ACR-70 response at six months. However, at 12 months, the 
abatacept-treated patients also showed signiﬁ  cantly higher 
serious adverse events, serious infections, and withdrawals 
due to adverse events (Weinblatt et al 2007).Biologics: Targets & Therapy 2008:2(2) 246
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The results of the above studies suggest that practitioners 
should proceed with extreme caution when combining 
biologics (Genovese et al 2004; Weinblatt et al 2006, 2007). 
Importantly, however, none of these studies appeared to 
include patients treated with rituximab. This is a particularly 
difﬁ  cult matter, because the clinical and biological effect of 
a single course of rituximab can last six months or longer 
(Edwards et al 2004; Cohen et al 2006; Emery et al 2006; 
Leandro et al 2006). Genovese and colleagues (2006) 
presented data at the 2006 ACR conference showing that of 
78 patients who received TNF inhibitor therapy following 
a course of rituximab, the rate of serious infections was 
7.62 per 100 person-years after the TNF inhibitors were 
started, compared with 5.23 per 100 person-years prior 
to the TNF inhibitor course. These differences were not 
statistically signiﬁ  cant, as they were based upon a total of 
seven events. However, details of the patient’s B-cell levels 
were not provided, except that they were said to be below 
the normal limits in all of the patients (Genovese et al 2006). 
Clearly, more studies are required regarding the safety of 
biologics following a treatment course of rituximab before 
any recommendations can be offered.
Summary
Biologics are routinely used in adult and pediatric arthritis. 
Overall, they have been remarkably effective, changing the 
outlook for a generation of patients afﬂ  icted with these disor-
ders. Most of the studies on biologics have focused on TNF 
inhibitors, but emerging evidence, particularly in adults, has 
suggested that other therapies may be effective as well, even in 
patients who have failed TNF inhibitors (Genovese et al 2005; 
Cohen et al 2006). Aside from the TNF inhibitors, there is 
minimal published pediatric data for these therapies, although 
anakinra and tocilizumab have both shown promise in the 
population of children with SOJIA (Pascual et al 2005; Woo 
et al 2005; Yokota et al 2008) and unpublished data suggests 
that abatacept may be effective JIA (Lovell et al 2006c).
As expected, safety has emerged as an important 
consideration in the use of biologic therapy. Overall, the 
randomized trials have generally shown these therapies to be 
well-tolerated, but the limitations of these studies, including their 
small size, relatively short duration of follow-up, and exclusion 
of patients who may be at greater risk of complications, limits 
their generalizability, and thus, post-marketing data assumes a 
particularly important role in their ongoing evaluation (Pincus 
and Stein 1997). Here again, the biologics have generally been 
found to be well-tolerated; however, rare and occasionally 
irreversible or even lethal side effects have emerged in adults 
and even rarely in children; moreover, the absence of speciﬁ  c 
safety signals for some of these therapies, particularly in 
pediatrics, can hardly be taken of evidence of safety and 
tolerability given the dearth of pediatric data.
A limitation of all biologics is that success is measured 
in improvement from baseline; remission is rarely a reported 
outcome in studies. This has tempted rheumatologists to 
combine two or more biologics, hoping for an additive effect; 
unfortunately, the limited data published to date has shown 
minimal beneﬁ  t with increased harms from this approach 
(Genovese et al 2004; Weinblatt et al 2006, 2007). Poten-
tial risks or beneﬁ  ts of biologics use following a course of 
rituximab are largely unknown.
Conclusion
As a group, biologics clearly have a place in the management 
of adult arthritis. Pediatric data is limited, and further studies 
are needed. In the meantime, pediatric rheumatologists will 
continue to learn important safety and efﬁ  cacy lessons from 
the adult rheumatology experience.
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